MintNeuro raises £3.8m to commercialise neural chips

London-based MintNeuro has secured £3.8m to commercialise chips for devices that interact with the brain and nervous system, in a funding round led by Odyssey Ventures.

The Imperial College spinout will also use the investment to increase shipments of pre-production chips to partners and build its presence in the US, BusinessCloud reported on 10 October 2026.

What happened

JSK Investments SICAV a.s., 33East and Alumni Ventures joined the round. Existing backers Empirical Ventures and Jumpspace Ventures invested again, bringing together European and American investors specialising in deep technology, medical technology and early-stage businesses.

The funding follows a multi-year supply agreement signed with Motif during 2026. MintNeuro will provide chips for a minimally invasive neurostimulator whose initial intended application is treatment-resistant depression.

That agreement gives the business a commercial customer alongside its development work. Other neural-device manufacturers and research teams are testing or incorporating MintNeuro’s technology, although the announcement does not identify them or disclose their number.

The investment adds to UK early-stage funding activity that includes Manchester Angels reaching 22 investments following two further deals.

The background

MintNeuro is concentrating primarily on medical uses. Its longer-term objective is to establish its technology as a standard chip platform for brain-computer interfaces, rather than focus solely on a single device or treatment.

Its modular semiconductor platform is designed to detect and process neural signals and deliver electrical stimulation to specific targets. The approach is intended to help device developers reduce size and energy consumption while moving their work from research towards clinical use.

The technical challenge extends beyond computing performance. Chips used in neural devices must meet particular requirements for power consumption, physical dimensions, safety and signal quality; a shortage of suitable components is constraining development, according to the announcement.

Neural devices are being developed for diagnosis and treatment across neurological and psychiatric conditions, including Parkinson’s disease, epilepsy, depression and hearing loss. These are wider applications for the field, not a list of treatments already delivered by MintNeuro products.

The commercialisation challenge has parallels elsewhere in UK technology funding, with Neela Biotech raising £2.1m for a waste-to-aviation-fuel pilot.

What people are saying

Petra Cihlářová, investment director of JSK’s venture capital sub-fund, identified hardware availability as the principal barrier to progress in neurotechnology. She said the investment case rested on MintNeuro’s technical team, functioning chips and first long-term commercial agreement.

Co-founder and chief executive Dorian Haci said JSK’s healthcare contacts and network across Europe and the US would help the company reach device developers and clinicians. He also pointed to the founders’ experience of building businesses internationally as support for MintNeuro’s next stage of commercial growth.

JSK was established in 2025 as a self-managed investment fund led by Simona Kijonková. It mainly makes direct equity investments in Czech and other European businesses, combining funding with strategic and operational support.

The private funding comes alongside wider UK innovation initiatives, including the Government’s £1bn innovation plan and mayoral funding. The MintNeuro announcement does not identify any connection to that programme.

What happens next

MintNeuro’s immediate priorities are product commercialisation, greater distribution of pre-production chips and expansion of its US operations. The announcement gives no launch date, shipment target or breakdown of how the £3.8m will be allocated.

The Motif contract provides a multi-year supply commitment, but its financial value and expected chip volumes have not been disclosed. Nor does the funding announcement set out a clinical timetable for the neurostimulator.